241 related articles for article (PubMed ID: 18724294)
1. Current status of autologous hematopoietic stem cell transplantation in myeloma.
Mehta J; Singhal S
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S28-S34. PubMed ID: 18724294
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
Mehta J; Singhal S
Bone Marrow Transplant; 2007 Dec; 40(12):1101-14. PubMed ID: 17680020
[TBL] [Abstract][Full Text] [Related]
3. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
[TBL] [Abstract][Full Text] [Related]
4. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
Björkstrand B; Gahrton G
Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
6. [Hematopoietic stem cell transplantation in multiple myeloma].
Vela-Ojeda J; Ruiz-Esparza MA
Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent.
Zomas A; Anagnostopoulos N; Dimopoulos MA
Bone Marrow Transplant; 2000 Jun; 25(12):1319-20. PubMed ID: 10871741
[TBL] [Abstract][Full Text] [Related]
8. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review.
Hahn T; Wingard JR; Anderson KC; Bensinger WI; Berenson JR; Brozeit G; Carver JR; Kyle RA; McCarthy PL
Biol Blood Marrow Transplant; 2003 Jan; 9(1):4-37. PubMed ID: 12533739
[TBL] [Abstract][Full Text] [Related]
9. The role of autologous stem cell transplantation in the management of multiple myeloma.
Fermand JP; Brechignac S
Pathol Biol (Paris); 1999 Feb; 47(2):199-202. PubMed ID: 10192889
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome.
Zeiser R; Deschler B; Bertz H; Finke J; Engelhardt M
Bone Marrow Transplant; 2004 Dec; 34(12):1057-65. PubMed ID: 15516937
[TBL] [Abstract][Full Text] [Related]
11. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
12. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK
Expert Rev Anticancer Ther; 2006 Mar; 6(3):343-60. PubMed ID: 16503852
[TBL] [Abstract][Full Text] [Related]
13. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.
Lenhoff S; Hjorth M; Turesson I; Westin J; Gimsing P; Wislöff F; Ahlberg L; Carlson K; Christiansen I; Dahl IM; Forsberg K; Brinch L; Hammerström J; Johnsen HE; Knudsen LM; Linder O; Mellqvist UH; Nesthus I; Nielsen JL;
Haematologica; 2006 Sep; 91(9):1228-33. PubMed ID: 16956822
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy.
Kumar S; Lacy MQ; Dispenzieri A; Rajkumar SV; Fonseca R; Geyer S; Allmer C; Witzig TE; Lust JA; Greipp PR; Kyle RA; Litzow MR; Gertz MA
Bone Marrow Transplant; 2004 Jul; 34(2):161-7. PubMed ID: 15133489
[TBL] [Abstract][Full Text] [Related]
15. [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)].
Lokhorst H; Huijgens PC; Raymakers R; Bos GM; Vellenga E; Wijermans PW; Sonneveld P;
Ned Tijdschr Geneeskd; 2005 Apr; 149(15):808-13. PubMed ID: 15850271
[TBL] [Abstract][Full Text] [Related]
16. The evolving background for high-dose treatment for myeloma.
Sirohi B; Powles R; Harousseau JL; Anderson KC
Bone Marrow Transplant; 2007 Dec; 40(12):1097-100. PubMed ID: 17906702
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation in the elderly including pre- and post-treatment options.
Kumar SK; Hayman SR; Kyle RA
Bone Marrow Transplant; 2007 Dec; 40(12):1115-21. PubMed ID: 17680019
[TBL] [Abstract][Full Text] [Related]
18. Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 years.
Corso A; Mangiacavalli S; Barbarano L; Alessandrino EP; Cairoli R; Morra E; Lazzarino M;
Cancer; 2007 Jun; 109(11):2273-8. PubMed ID: 17440982
[TBL] [Abstract][Full Text] [Related]
19. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients.
Martino M; Console G; Callea V; Stelitano C; Massara E; Irrera G; Messina G; Morabito F; Iacopino P
Eur J Haematol; 2007 Jan; 78(1):35-40. PubMed ID: 17042773
[TBL] [Abstract][Full Text] [Related]
20. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?
Klepin HD; Hurd DD
Bone Marrow Transplant; 2006 Nov; 38(9):585-92. PubMed ID: 16953209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]